Bliss Gvs Pharma
BSE: 506197 | NSE: BLISSGVS | ISIN: INE416D01022 | SECTOR: Biotechnology & DrugsOpen
124.45High
131.10Low
120.75Prev Close
124.45P/E
-Median P/E
-P/B
-Median P/B
-Market Cap
13.38BVolume
46.00KVol. (20 day Avg.)
0PEG
-Div.Yield
-Bid
127.65Ask
127.95
Company Description
- Biotechnology & Drugs
BSE
506197NSE
BLISSGVSISIN
INE416D01022
Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Company Officers
Deepak Sawant
Chief Financial OfficerAditi Bhatt
Chief Compliance Officer, Company SecretaryGagan Sharma
Managing Director, Executive DirectorShruti Rao
Whole-Time DirectorVibha Sharma
Whole-Time Director